Article 14 May 2024 US FTC Continues Aggressive Scrutiny Of Pharmaceutical Patents Listed In The Orange Book United States IP
Article 06 Dec 2022 Orphan Exclusivity In Catalyst's Aftermath: FDA Inaction Leaves Rare Disease Sponsors In Limbo United States Healthcare